Candel Therapeutics, Inc. · NASDAQ:CADL
Candel Therapeutics — AUA 2026
17 slides from Candel Therapeutics's conference presentation, May 2026
Slide 1: Extended follow-up shows accumulating benefit with aglatimagene besadenovec + prodrug in localized prostate cancer
Extended follow-up shows accumulating benefit for patients treated with aglatimagene besadenovec (CAN-2409) + prodrug in combination with standard-of-care external beam radiation (EBRT) in men with localized prostate cancer: update from a randomized placebo-controlled phase 3 clinical trial Mark Gar
Slide 2: Disclosures
Disclosures Dr. Garzotto has served as a clinical trial investigator for Astellas Pharma, Candel Therapeutics, Merck & Co., and Pfizer. He also served as a consultant to Candel Therapeutics 2
Slide 3: Unmet need in localized prostate cancer
Unmet need in localized prostate cancer Global concern: approximately 1.4 million new cases of prostate cancer in 20201 Incidence in US2 INTERMEDIATE HIGH LOW RISK RISK RISK 65K 109K 43K Patients Currently Receiving Radiotherapy ~65K (~43%) Ultimate goal of curative treatment is prevention of cancer
Slide 4: Aglatimagene besadenovec + prodrug: Overview of mechanism of action
Aglatimagene besadenovec + prodrug: Overview of mechanism of action 1 Intratumoral gene 2 Prodrug activation 3 Radiotherapy synergy 4 Anti-tumor 5 Local and systemic delivery immune priming disease control Aglatimagene is a replication- HSV-TK converts prodrug Radiation synergizes with Tumor cell de
Slide 5: Aglatimagene besadenovec injection procedure
Aglatimagene besadenovec injection procedure PROCEDURE STEPS Patient Position 1 • Position: knee-chest (lateral) or lithotomy, as in standard TRUS- guided biopsy • Approach: transrectal or transperineal — both acceptable • Setting: in-office or ASC; local block or IV sedation typically sufficient II
Slide 6: Injection and radiation sequencing schedule
Injection and radiation sequencing schedule t -14d t=0d t +14d 14 days prior to radiotherapy Start of RT 14 days after prior injection 14-day course 14-day course 14-day course valacyclovir valacyclovir valacyclovir INJECTION SCHEDULE INJECTION #1 (t−14d) INJECTION #2 (t=0) INJECTION #3 (t+14d) RT M
Slide 7: Phase 3 clinical trial of aglatimagene in newly diagnosed, intermediate- to high-risk, localized prostate cancer
Phase 3 clinical trial of aglatimagene in patients with newly diagnosed, intermediate- to high-risk, localized prostate cancer NCT01436968 Aglatimagene + valacyclovir Primary endpoints • Disease-free survival (time to (3 injection courses + radiotherapy cancer recurrence or death due n=745 with or w
Slide 8: Disease-free survival in localized prostate cancer treated with curative intent
Disease-free survival in localized prostate cancer treated with curative intent DFS: time from randomization to prostate cancer recurrence (biopsy, clinical, or radiographic evidence), metastasis, or death from any cause Prostate cancer-specific DFS: time from randomization to prostate cancer recurr
Slide 9: Demographic and baseline characteristics of randomized patients
Demographic and baseline characteristics of randomized patients Aglatimagene + prodrug Placebo + prodrug Total ITT population (N=745) (N=496) (N=249) (N=745) Median age (yrs) 69 68 69 Race, n (%) White/Caucasian 385 (77.6) 206 (82.7) 591 (79.3) Black/African American 93 (18.8) 28 (11.2) 121 (16.2) A
Slide 10: Aglatimagene significantly improved prostate cancer-specific disease-free survival after extended follow-up
Aglatimagene significantly improved prostate cancer-specific disease-free survival after extended follow-up (ITT, N = 745) Aglatimagene + SoC resulted in 39% improvement in prostate cancer-specific DFS compared to PBO + SoC Only 2 deaths due to prostate cancer (1 each arm) after median follow- HR=0.
Slide 11: Longer time to salvage anticancer therapy and biochemical failure in aglatimagene arm
Longer time to salvage anticancer therapy and biochemical failure observed in aglatimagene arm (ITT, N=745) Time to new anticancer therapy Time to biochemical failure (nadir+2) HR=0.72; 95% CI 0.39 – 1.31 HR=0.72; 95% CI 0.40 – 1.31 DATA CUTOFF: MAR 15, 2026 Mark Garzotto, MD | AUA 2026, Washington
Slide 12: Lower incidence of and increased time to metastasis in aglatimagene arm
Lower incidence of and increased time to metastasis observed in aglatimagene arm (ITT, N = 745) Time to metastasis Aglatimagene + SoC cohort experienced a lower rate of metastases Agla 8/496 (1.6%), PBO 7/249 (2.8%) HR=0.58; 95% CI 0.21 – 1.59 DATA CUTOFF: MAR 15, 2026 Mark Garzotto, MD | AUA 2026,
Slide 13: Improved prostate cancer-specific DFS in intermediate-risk prostate cancer
Aglatimagene significantly improved prostate cancer-specific disease- free survival in intermediate-risk prostate cancer (n = 635) Aglatimagene + SoC resulted in 41% improvement in prostate cancer-specific DFS compared to PBO + SoC HR=0.59; 95% CI 0.41 - 0.84 p=0.0034 DATA CUTOFF: MAR 15, 2026 Mark
Slide 14: Longer time to salvage therapy and biochemical failure in intermediate-risk prostate cancer
Longer time to salvage anticancer therapy and biochemical failure observed in aglatimagene arm in intermediate-risk prostate cancer (n = 635) Time to new anticancer therapy Time to biochemical failure (nadir+2) HR=0.51; 95% CI 0.24 - 1.1 HR=0.48; 95% CI 0.22 – 1.03 DATA CUTOFF: MAR 15, 2026 Mark Gar
Slide 15: Lower incidence of and increased time to metastases in intermediate-risk prostate cancer
Lower incidence of and increased time to metastases observed in aglatimagene arm in intermediate-risk prostate cancer (n = 635) Time to metastasis Aglatimagene + SoC cohort experienced lower rate of metastatic disease Agla 1/422 (0.24%), PBO 5/213 (2.35%) HR=0.1; 95% CI 0.01 – 0.85 DATA CUTOFF: MAR
Slide 16: Aglatimagene with SoC radiation +/- ADT was generally well tolerated
Aglatimagene in combination with SoC radiation +/- ADT was generally well tolerated 0 5.8% vs 7.3% 5.4% vs 6.0% Grade ≥4 TRAEs SAE incidence Discontinuation due to AEs No serious treatment-related events Aglatimagene + SOC vs placebo + SOC Aglatimagene + SOC vs placebo + SOC Treatment related AEs >5
Slide 17: Accumulating clinical benefit with aglatimagene plus EBRT after extended follow-up
Accumulating clinical benefit for patients treated with aglatimagene in combination with EBRT after extended follow-up Previously presented primary endpoint demonstrated statistically significant improvement in DFS as well as increased pathological complete response in 2-year biopsies1, known to be